Compare NUVB & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | RH |
|---|---|---|
| Founded | 2018 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | N/A | 1998 |
| Metric | NUVB | RH |
|---|---|---|
| Price | $8.47 | $165.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 16 |
| Target Price | $10.63 | ★ $260.27 |
| AVG Volume (30 Days) | ★ 10.3M | 952.1K |
| Earning Date | 11-03-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 207.98 |
| EPS | N/A | ★ 5.35 |
| Revenue | $26,748,000.00 | ★ $3,337,241,000.00 |
| Revenue This Year | $609.55 | $13.15 |
| Revenue Next Year | $197.91 | $10.14 |
| P/E Ratio | ★ N/A | $28.63 |
| Revenue Growth | ★ 1137.19 | 9.56 |
| 52 Week Low | $1.54 | $123.03 |
| 52 Week High | $8.95 | $457.26 |
| Indicator | NUVB | RH |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 53.18 |
| Support Level | $7.80 | $151.71 |
| Resistance Level | $8.95 | $166.52 |
| Average True Range (ATR) | 0.51 | 8.41 |
| MACD | -0.04 | 1.74 |
| Stochastic Oscillator | 74.78 | 63.94 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 23 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.